---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-003852"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T07:21:45.291650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe

## Summary
- Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.
- Net cash used in ops averaged $1.4M/month, down ~50% vs Q1 2024; cash balance $2.6M at March 31, 2025.
- Post-quarter closed $6.25M convertible loan note (24-month, 6-month repayment holiday).
- Confidential licensing discussions with >10 companies; combined market cap of seven >$600B.
- Goal to be cash neutral on full-year 2025 basis via licensing receipts and cost reduction.

## SEC filing metadata
- accession: 0001477932-25-003852
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793225003852/0001477932-25-003852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793225003852/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-003852
- JSON: https://secwatch.observer/filing/0001477932-25-003852.json
- Plain text: https://secwatch.observer/filing/0001477932-25-003852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.